<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01238835</url>
  </required_header>
  <id_info>
    <org_study_id>2009-06</org_study_id>
    <nct_id>NCT01238835</nct_id>
  </id_info>
  <brief_title>PREVAIL-TA: Placement of Aortic Balloon Expandable Transcatheter Valves Trial (Europe)</brief_title>
  <official_title>Placement of AoRtic Balloon Expandable Transcatheter VAlves TrIaL (TransApical)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single arm, prospective multicenter non-randomized confirmatory clinical trial evaluating&#xD;
      the Edwards SAPIEN XT™ transcatheter heart valve (model 9300TFX; &quot;study valve&quot;), the next&#xD;
      generation Ascendra™ transapical delivery system, and crimper accessories.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: The purpose of this trial is to evaluate the acute safety and effectiveness of the&#xD;
      SAPIEN XT™ study valve and next generation Ascendra™ delivery components.&#xD;
&#xD;
      Follow-up Intervals: Subject data collection will include clinical information at baseline&#xD;
      and during the index procedure. Subjects will undergo clinical follow-up at discharge, 30&#xD;
      days, 6 month annually for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2009</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Deaths</measure>
    <time_frame>30 days</time_frame>
    <description>Number of death at 30-days from the index procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Stroke</measure>
    <time_frame>30-days</time_frame>
    <description>Total Number of Participants with a Stroke.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>TAVR-TA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter valve replacement with transapical access</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SAPIEN XT™ Transapical aortic valve replacement</intervention_name>
    <description>Transcatheter aortic valve implantation via the transapical approach</description>
    <arm_group_label>TAVR-TA</arm_group_label>
    <other_name>Sapien XT</other_name>
    <other_name>Next generation Ascendra delivery system inclusive accessory</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          1. EuroSCORE of ≥ 15 %&#xD;
&#xD;
          2. Severe senile degenerative aortic valve stenosis&#xD;
&#xD;
          3. Symptomatic aortic valve stenosis&#xD;
&#xD;
          4. Informed consent&#xD;
&#xD;
          5. Compliance&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          1. Logistic Euroscore &gt; 40 %&#xD;
&#xD;
          2. Evidence of an acute myocardial infarction&#xD;
&#xD;
          3. Congenital unicuspid or congenital bicuspid valve/ non-calcified&#xD;
&#xD;
          4. Mixed aortic valve disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Dr. Thomas Walther</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kerckhoff Klinik</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Olaf Wendler</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universitat Wien Univ.Klinik f.Chirurgie</name>
      <address>
        <city>Wien</city>
        <zip>1019</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôspital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-Und Gefasszentrum Bad Bevensen</name>
      <address>
        <city>Bad Bevensen</city>
        <zip>29549</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-und-Gefass Klinik</name>
      <address>
        <city>Bad Neustadt An Der Saale</city>
        <zip>97616</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz-und Diabeteszentrum NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schüchtermann-Klinik</name>
      <address>
        <city>Bad Rothenfelde</city>
        <zip>49214</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center University Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Dresden GmbH</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Essen, West German Heart Center</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac Surgery Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76185</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04829</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Heart Center Munich</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Munich-Grosshadern</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Munich-Bogenhausen</name>
      <address>
        <city>Munich</city>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas' Hospital - NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 26, 2010</study_first_submitted>
  <study_first_submitted_qc>November 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2010</study_first_posted>
  <results_first_submitted>September 27, 2020</results_first_submitted>
  <results_first_submitted_qc>October 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2020</results_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sapien XT Valve</keyword>
  <keyword>Valvular Heart Disease</keyword>
  <keyword>Aortic Stenosis</keyword>
  <keyword>Heart Valve Therapy</keyword>
  <keyword>Transapical</keyword>
  <keyword>Transcatheter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>One patient withdrew from the study prior to procedure and one patient did not continue to procedure due to poor health.</recruitment_details>
      <pre_assignment_details>Two enrolled subjects did not enter the procedure room.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TAVR-TA</title>
          <description>Transcatheter valve replacement with transapical access&#xD;
SAPIEN XT™ Transapical aortic valve replacement: Transcatheter aortic valve implantation via the transapical approach</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="218"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site early discontinuation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>As treated population</population>
      <group_list>
        <group group_id="B1">
          <title>TAVR-TA</title>
          <description>Transcatheter valve replacement with transapical access&#xD;
SAPIEN XT™ Transapical aortic valve replacement: Transcatheter aortic valve implantation via the transapical approach</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="218"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.2" spread="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Logistic EuroSCORE</title>
          <description>The logistic European System for Cardiac Operative Risk Evaluation (logistic EuroSCORE) measures patient risk of mortality or morbidity at the time of cardiovascular surgery on a scale that ranges from 0% to 100%, with higher numbers indicating greater risk of operative mortality.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.0" spread="7.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA Class</title>
          <description>New York Heart Association (NYHA), functional classification of heart failure based on how much a patient is limited during physical activity. The rating ranges from I-IV. I = no limitations of physical activity; II = slight limitations of physical activity, ordinary physical activity results in fatigue, palpitation, shortness of breath; III = marked limitations of physical activity, less than ordinary activity causes fatigue, palpitation, or shortness of breath.; IV = unable to carry on any physical activity without discomfort, symptoms of heart failure at rest.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Class I/II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class III/IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Deaths</title>
        <description>Number of death at 30-days from the index procedure.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TAVR-TA</title>
            <description>Transcatheter valve replacement with transapical access&#xD;
SAPIEN XT™ Transapical aortic valve replacement: Transcatheter aortic valve implantation via the transapical approach</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Deaths</title>
          <description>Number of death at 30-days from the index procedure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Stroke</title>
        <description>Total Number of Participants with a Stroke.</description>
        <time_frame>30-days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TAVR-TA</title>
            <description>Transcatheter valve replacement with transapical access&#xD;
SAPIEN XT™ Transapical aortic valve replacement: Transcatheter aortic valve implantation via the transapical approach</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Stroke</title>
          <description>Total Number of Participants with a Stroke.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 Years</time_frame>
      <desc>All adverse events are site reported</desc>
      <group_list>
        <group group_id="E1">
          <title>TAVR-TA</title>
          <description>Transcatheter valve replacement with transapical access&#xD;
SAPIEN XT™ Transapical aortic valve replacement: Transcatheter aortic valve implantation via the transapical approach</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="201" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulopathy / Hematological Disorder</sub_title>
                <counts group_id="E1" events="68" subjects_affected="53" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Arrhythmia Supraventricular</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Arrhythmia Ventricular</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Conduction Defects w/o Permanent Pacemaker</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Conduction Defects with Permanent Pacemaker</sub_title>
                <counts group_id="E1" events="35" subjects_affected="32" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Heart Failure</sub_title>
                <counts group_id="E1" events="90" subjects_affected="58" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Mitral Regurg. ( 3+ or 4+)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Disorder</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastro-Intestinal Event</sub_title>
                <counts group_id="E1" events="39" subjects_affected="29" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Multiple Organ Failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Non-Struct Valve Dysf. (Not PVL)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Orthopedic Event</sub_title>
                <counts group_id="E1" events="23" subjects_affected="17" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="114" subjects_affected="67" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Valve Embolization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Infection / Inflammation</sub_title>
                <counts group_id="E1" events="90" subjects_affected="62" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Access Related Complication - Thoracic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Access Related Complication - Ventricle</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Annular Dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Bleeding - Procedure</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Bleeding - Trauma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Mitral Valve Compromise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Struct Valve Deterioration (SVD)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Thoracic Wound Comp.</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Ventricular / Myocardial Injury / Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic Disorder</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="24" subjects_affected="16" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological Event Minor - Not Stroke</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Neurological Event Severe - Not Stroke</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Stroke - Embolic / Ischemic Origin</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Stroke - Unknown Origin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Delivery System Malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Perivalvular Leak (1+ or 2+)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Perivalvular Leak (3+ or 4+)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Transitory Psychotic Syndrome</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure requiring Permanent Dialysis (&gt;30d)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Renal Insufficency not requiring Dialysis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Renal Insufficiency / Failure requiring Temporary Dialysis (&lt; or = 30d)</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="31" subjects_affected="28" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Respiratory Comp / Failure not requ. Resp Assistance</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Respiratory Comp / Failure requ. Resp Assistance</sub_title>
                <counts group_id="E1" events="31" subjects_affected="25" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Bleeding - Not Trauma Not Procedure</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hemodynamic Collapse</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Vascular Event (Not Access-Related)</sub_title>
                <counts group_id="E1" events="27" subjects_affected="17" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="212" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulopathy / Hematological Disorder</sub_title>
                <counts group_id="E1" events="38" subjects_affected="34" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia Supraventricular</sub_title>
                <counts group_id="E1" events="75" subjects_affected="64" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Conduction Defects w/o Permanent Pacemaker</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Heart Failure</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastro-Intestinal Event</sub_title>
                <counts group_id="E1" events="49" subjects_affected="36" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Orthopedic Event</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="253" subjects_affected="122" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Peripheral Edema</sub_title>
                <counts group_id="E1" events="34" subjects_affected="30" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection / Inflammation</sub_title>
                <counts group_id="E1" events="142" subjects_affected="94" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bleeding - Procedure</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic Disorder</sub_title>
                <counts group_id="E1" events="31" subjects_affected="27" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological Event Minor - Not Stroke</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Transitory Psychotic Syndrome</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Insufficency not requiring Dialysis</sub_title>
                <counts group_id="E1" events="39" subjects_affected="36" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="143" subjects_affected="130" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Respiratory Comp / Failure not requ. Resp Assistance</sub_title>
                <counts group_id="E1" events="32" subjects_affected="25" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Edwards THV Clinical Affairs</name_or_title>
      <organization>Edwards Lifesciences</organization>
      <phone>949-250-2500</phone>
      <email>THV_CT.gov@edwards.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

